On July 30, IQVIA rose 5.03% overnight, trading at $260.0/share, with turnover of $75,200. On the news front, RBC Capital Markets raised its price target on IQVIA from $221 to $247 on July 29, maintaining its outperform rating, citing a favorable setup for margin expansion into 2027.

RBC noted that IQVIA benefits from multiple tailwinds including operational efficiencies, margin accretion through the commercial solutions segment, and operating leverage. The brokerage highlighted that the company's tech differentiation is gaining market share, and the inflection in contract research organization activity should continue to accelerate. RBC also pointed to IQVIA's Q2 beat and raise on record bookings growth as evidence of sustainable growth in its R&D solutions business, adding that fiscal 2026 EBITDA guidance is achievable as AI-driven efficiencies should largely offset higher pass-through costs.

This follows IQVIA's strong Q2 results reported on July 28, with adjusted EPS of $3.15 beating estimates of $3.03, and revenue of $4.37 billion exceeding the $4.30 billion consensus. The company also raised full-year guidance, projecting adjusted EPS of $12.80-$13.00 and revenue of $17.28-$17.48 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)